Happel David 4

What Happened

• David Happel, President & CEO and a director of Sagimet Biosciences, disposed of 12,101 shares on Feb 10, 2026 at $5.36 per share, for proceeds of $64,865. The Form 4 lists the transaction as a sale (S).

Key Details

• Transaction date and price: Feb 10, 2026 — 12,101 shares at $5.36 each.
• Total proceeds: $64,865.
• Shares owned after transaction: not specified in the provided filing excerpt (see full Form 4 for post-transaction holdings).
• Footnote: F1 — these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units; the sales were automatic and not at the reporting person’s discretion.
• Filing date: Feb 12, 2026 — reported on the Form 4 within the usual two-business-day window.

Context

• This was a routine "sell-to-cover" associated with RSU vesting (automatic tax-withholding), not an open-market sell initiated as a discretionary trade. Such transactions are common and typically reflect tax mechanics rather than a change in the insider’s view of the company.